Loading
Total declarations
Companies
▲ Purchases (2 ops.)
▼ Sales (0 ops.)
Latest filing published 03 Jul 2025 for Inozyme Pharma, Inc., €74k. Read the official filing
Insider track record
Disclosed buys
2
Disclosed sells
0
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Signal history
Matthew Winton: trading record in brief
Filings by Matthew Winton span 2 companies, the busiest being Inozyme Pharma, Inc. and CervoMed Inc. In total, 7 filings cover trades dated from 28 March 2024 to 17 November 2025.
Purchases make up the whole of the open-market record (2 purchases, €90k). Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. Outside the open market, there are 4 share grants. So far in 2025, the count stands at 2 purchases and no sales.
Most recently, on 19 November 2025, the filings show an open-market purchase worth €25k in CervoMed Inc. Filings reach the SEC (Form 4) feed a median of 2 days after the trade. For comparison, the SEC allows two business days to file a Form 4. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Companies and markets linked to Matthew Winton
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations5 total
21,743 shares@ US$4.00Common StockSEC:0000950170-25-094098:0
14,355 shares@ US$0.7433.0% of flowCommon StockSEC:0000950170-25-090868:0
2,490 shares@ US$0.779.6% of flowCommon StockSEC:0000950170-25-049393:0
1,710 shares@ US$4.4537.1% of flowCommon StockSEC:0000950170-24-112694:0
3,188 shares@ US$3.3353.3% of flowCommon StockSEC:0000950170-24-041300:0
5 of 5 declarations
